Dergiler / Journal of the Turkish-German Gynecological Association / 2015 / Cilt: 16 - Sayı: 1

Efficacy of a real time optoelectronic device (TruScreen ) in detecting cervical intraepithelial pathologies: A prospective observational study

Sayfa
41–44
Yayın Tarihi
2022-10-18
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

The combination of TruScreen and HPV screening was not able to demonstrate a significant rise of effectiveness in screening.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: To assess the effect of TruScreen (an objective optoelectronic cervical screening device) in improving the sensitivity of cervicalscreening programs either alone or in combination with Papanicolaou (PAP) smear or human papilloma virus (HPV) DNA screening.Material and Methods: Our study was performed in 285 patients with abnormal Pap test results.
📊
Temel Bulgular & Veri:Consistency and differences between the tests were compared with cervical biopsy results.Results: TruScreen was found to be an approach method in the determination of cervical pathologies (ROC curve area underlined=0.606)and with an 89.5% negative predictive value.
💡
Sonuç & Katkı:The combination of TruScreen and HPV screening was not able to demonstrate a significant rise of effectiveness in screening.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Objective: To assess the effect of TruScreen (an objective optoelectronic cervical screening device) in improving the sensitivity of cervicalscreening programs either alone or in combination with Papanicolaou (PAP) smear or human papilloma virus (HPV) DNA screening.Material and Methods: Our study was performed in 285 patients with abnormal Pap test results. TruScreen and HPV screening methodswere performed in all participants. Consistency and differences between the tests were compared with cervical biopsy results.Results: TruScreen was found to be an approach method in the determination of cervical pathologies (ROC curve area underlined=0.606)and with an 89.5% negative predictive value. HPV screening remains a counterpart to TruScreen with a 0.620 area underlined in the ROC curveand an 83% negative predictive value.Conclusion: As determined in our study, TruScreen with a sensitivity of 86.1% can be used as a screening test with instant and not professionaldependent results for cervical cancer screening. Avoiding from subjectivity in interpretation of Pap smears and requirement for pathologists, Tru -Screen can be a used for cervical cancer screening especially in countries with a low socio-economic status. The combination of TruScreen and HPV screening was not able to demonstrate a significant rise of effectiveness in screening.

🔖

Bu Makaleye Atıf Yap

DANIŞMAN, N., YILDIZ, Y., ÖZGÜ, E., SALMAN, B. Ö., GÜNGÖR, T., ÖZ, M. (2022). Efficacy of a real time optoelectronic device (TruScreen ) in detecting cervical intraepithelial pathologies: A prospective observational study. Journal of the Turkish-German Gynecological Association, Cilt: 16 - Sayı: 1, 41–44. https://ajindex.com/articles/567543

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (13)

  1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015
  2. E359-86. [CrossRef] 2. Thomas DB, Qin Q, Kuypers J, Kiviat N, Ashley RL, Koetsawang A, et al. Human papillomaviruses and cervical cancer in Bangkok. II. Risk factors for in situ and invasive squamous cell cervical carcino - mas. Am J Epidemiol 2001
  3. [CrossRef] 3. Cuzick J, Szarewski A, Cubie H, Hulman G, Kitchener H, Luesley D, et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet 2003
  4. [CrossRef] 4. Stoy RD, Foster KR, Schwan HP. Dielectric properties of mamma - lian tissues from 0.1 to 100 MHz: a summary of recent data. Phys Med Biol 1982
  5. [CrossRef] 5. Barrow AJ, Wu SM. Impedance measurements for cervical cancer diagnosis. Gynecol Oncol 2007
  6. [CrossRef] 6. Coppleson M, Reid BL, Skladnev VN, Dalrymple JC. An electronic approach to the detection of pre-cancer and cancer of the uter- ine cervix: a preliminary evaluation of Polarprobe. Int J Gynecol Cancer 1994
  7. [CrossRef] 7. Abdul S, Brown BH, Milnes P, Tidy JA. The use of electrical imped - ance spectroscopy in the detection of cervical intraepithelial neo - plasia. Int J Gynecol Cancer 2006
  8. [CrossRef] 8. Nygard JF, Nygard M, Skare GB, Thoresen SO. Screening histories of women with CIN 2/3 compared with women diagnosed with invasive cervical cancer: a retrospective analysis of the Norwegian Coordinated Cervical Cancer Screening Program. Cancer Causes Control 2005
  9. [CrossRef] 9. McCrory DC, Matchar DB, Bastian L, Datta S, Hasselblad V, Hickey J, et al. Evaluation of cervical cytology. Evid Rep Technol Assess (Summ) 1999
  10. Sung HY, Kearney KA, Miller M, Kinney W, Sawaya GF, Hiatt RA. Papanicolaou smear history and diagnosis of invasive cervical carcinoma among members of a large prepaid health plan. Cancer 2000
  11. [CrossRef] 11. Singer A, Coppleson M, Canfell K, Skladnev V, Mackellar G, Pisal N, Deery A. A real time optoelectronic device as an adjunct to the Pap smear for cervical screening: a multicenter evaluation. Int J Gynecol Cancer 2003
  12. [CrossRef] 12. Li W, Guo Y, Niu H, Jin S, Wang L. Application of TruScreen in detecting ASCUS patients. Asian Pac J Trop Med 2011
  13. [CrossRef] 13. Long S, Lei W, Feng Y, Lv D, Cai Y, Yang P.